mTOR inhibitor

systematic review meta-analysis network meta-analysis

Select advanced breast cancer (metastatic)renal-cell carcinoma (advanced) All type of patientuncoded clinical condition ***HR+ HER2 -       add-on to anti HER-2 agentcombination with endocrine therapymTor inihibitor everolimustemsirolimus vs CTvs endocrine therapy alone       1st lineHER-2 negativeHER-2 positiveHR positivensNAI failurepostmenopausalpreviously treated by taxanespreviously treated with endocrine therapytrastuzumab failure

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	death (overall survival) (12)progression or death (progression free survival PFS) (11)progression (Time to progression TTP) (3) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	death (overall survival)	progression or death (progression free survival PFS)
advanced breast cancer (metastatic)
everolimus
BOLERO-2, 2011        NCT	everolimus + exemestane	exemestane alone		HER-2 negative HR positive nsNAI failure previously treated with endocrine therapy	Low risk of bias	conclusive
TAMRAD , 2012      NCT	everolimus + tamoxifen	tamoxifen alone		1st line HER-2 negative HR positive postmenopausal previously treated with endocrine therapy	Risk of bias	suggesting
BOLERO-3, 2014      NCT	everolimus + trastuzumab + vinorelbine	trastuzumab + vinorelbine alone		HER-2 positive previously treated by taxanes trastuzumab failure	Low risk of bias	conclusive
temsirolimus
HORIZON, 2013      NCT	temsirolimus + letrozole	letrozole alone		1st line HR positive postmenopausal	Low risk of bias	negative
renal-cell carcinoma (advanced)
everolimus
RECORD-1, 2008      NCT	everolimus	placebo				suggesting
RECORD 3, 2014      NCT	everolimus	sunitinib				-
temsirolimus
ARCC (Hudes) temsirolimus alone, 2007      NCT	temsirolimus	interferon alpha				suggesting
INTORSECT, 2014      NCT	temsirolimus	sorafenib				negative